Thioredoxin as a marker for severity and prognosis of aneurysmal subarachnoid hemorrhage

Anti-Inflammatory Thioredoxin Family Proteins for Medicare, Healthcare and Aging Care

“…Increased levels of extracellular TRX have been reported in many pathological conditions associated with oxidative stress ( Table 1 ) [ 20 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 ]. The elevation of TRX in plasma or serum suggests the potential utility of TRX as a useful clinical parameter for inflammatory disorders.…”

Can we improve the prediction of complications and outcome in aneurysmal subarachnoid hemorrhage? The clinical implications of serum proteomics

“…A study found a significant elevation of TRX in 132 patients with aSAH (23.4 ± 12.2 ng/mL), compared with 132 controls (8.5 ± 4.0 ng/mL) association between serum TRX levels and modified Fischer score upon admission and 6 months' predictor of mortality and unfavorable outcome. The optimal cut-off value of serum Trx levels as a predictor for 6-month mortality was considered to be 25.1 ng/mL (Dai et al, 2016). TRX levels improved the predictive performance of GCS score for 6 months' outcome with a cutoff value of 20.3 ng/ml, but not for 1-week mortality or 6 months mortality when 112 patients with aSAH and 112 controls were studied (Pan et al, 2016).…”

Biospecimens and Molecular and Cellular Biomarkers in Aneurysmal Subarachnoid Hemorrhage Studies: Common Data Elements and Standard Reporting Recommendations

“…Emerging multiplex and precision medicine techniques have not been sufficiently studied in SAH. Additional emerging biomarkers implicated in immune function and inflammation include osteopontin, thioredoxin, and galectin-3 (Gal-3) [44][45][46][47]. As Gal-3 is involved in microglia activation and proliferation in response to ischemic injury it might be a specific indicator for secondary ischemic complications after SAH [47].…”